SMO and pancreatic neoplasm: Dual blockade of SMO and BRD4 might also contribute to prevent resistance to pan-selective BET inhibitors such as JQ1, because resistance to JQ1 can be mediated by GLI2-dependent upregulation of cMYC and targeting GLI2 restores JQ1 sensitivity in pancreatic cancer [42].